Evolution of Pfdhps and Pfdhfr Mutations Before and After Adopting Seasonal Malaria Chemoprevention in Nanoro, Burkina Faso

Overview

Journal Sci Rep

Specialty Science

Date 2024 Oct 16

PMID 39414909

Authors

Francis Emmanuel Towanou Bohissou

Paul Sondo

Juliana Inoue

Toussaint Rouamba

Berenger Kabore

Guetawende Job Wilfried Nassa

A Elisee Sie Kambou

Tiampan Edwig Traore

Victor Asua

Steffen Borrmann

Halidou Tinto

Jana Held

Affiliations

Soon will be listed here.

Abstract

Seasonal Malaria Chemoprevention consisting of monthly administration of amodiaquine/sulfadoxine-pyrimethamine to children aged 3-59 months during the transmission season could promote SP-resistance. Mutations in dihydrofolate reductase (Pfdhfr) and dihydropteroate synthase (Pfdhps) genes were assessed before and after SMC adoption in Burkina Faso. A total of 769 dried blood spots were selected from studies conducted in Nanoro, Burkina Faso, between 2010 and 2020. Of those, 299 were pre-SMC (2010-2012) and 470 were post-SMC-samples. Pfdhps and Pfdhfr genes were PCR-amplified and sequenced. A systematic review/meta-analysis of published studies conducted in Burkina Faso (2009-2023) was additionally performed. In Nanoro, the prevalence of Pfdhfr triple mutations (CIRNI) rose from 43.6% pre-SMC to 89.4% post-SMC (p < 0.0001). There was no mutation in Pfdhfr 164 and Pfdhps 540; Pfdhps A437G mutation increased from 63.9% (2010-2012) to 84.7% (2020) (p < 0.0001). The VAGKGS haplotype was 2.8% (2020). Pfdhfr/Pfdhps quintuple mutant IRN-436A437G rose from 18.6% (2010-2012) to 58.3% (2020) (p < 0.0001). Meta-analysis results from Burkina Faso showed an increase in mutations at Pfdhfr N51I, C59R, S108N, and Pfdhps A437G after SMC adoption. Post-SMC, the pyrimethamine-resistance marker prevalence increased, while the sulfadoxine-resistance marker prevalence remained stable. Detection of emerging PfdhpsVAGKGS haplotypes in 2020 underscores the importance of continuous SP-resistance monitoring.

References

Rosenthal P . The interplay between drug resistance and fitness in malaria parasites. Mol Microbiol. 2013; 89(6):1025-38. PMC: 3792794. DOI: 10.1111/mmi.12349. View

Some A, Zongo I, Compaore Y, Sakande S, Nosten F, Ouedraogo J . Selection of drug resistance-mediating Plasmodium falciparum genetic polymorphisms by seasonal malaria chemoprevention in Burkina Faso. Antimicrob Agents Chemother. 2014; 58(7):3660-5. PMC: 4068591. DOI: 10.1128/AAC.02406-14. View

Lo A, Faye B, Ba E, Cisse B, Tine R, Abiola A . Prevalence of molecular markers of drug resistance in an area of seasonal malaria chemoprevention in children in Senegal. Malar J. 2013; 12:137. PMC: 3652725. DOI: 10.1186/1475-2875-12-137. View

Tumwebaze P, Tukwasibwe S, Taylor A, Conrad M, Ruhamyankaka E, Asua V . Changing Antimalarial Drug Resistance Patterns Identified by Surveillance at Three Sites in Uganda. J Infect Dis. 2017; 215(4):631-635. PMC: 5853976. DOI: 10.1093/infdis/jiw614. View

Kublin J, Dzinjalamala F, Kamwendo D, Malkin E, Cortese J, Martino L . Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J Infect Dis. 2002; 185(3):380-8. DOI: 10.1086/338566. View

Staedke S, Sendagire H, Lamola S, Kamya M, Dorsey G, Rosenthal P . Relationship between age, molecular markers, and response to sulphadoxine-pyrimethamine treatment in Kampala, Uganda. Trop Med Int Health. 2004; 9(5):624-9. DOI: 10.1111/j.1365-3156.2004.01239.x. View

Heinberg A, Siu E, Stern C, Lawrence E, Ferdig M, Deitsch K . Direct evidence for the adaptive role of copy number variation on antifolate susceptibility in Plasmodium falciparum. Mol Microbiol. 2013; 88(4):702-12. PMC: 3654098. DOI: 10.1111/mmi.12162. View

Beshir K, Muwanguzi J, Nader J, Mansukhani R, Traore A, Gamougam K . Prevalence of Plasmodium falciparum haplotypes associated with resistance to sulfadoxine-pyrimethamine and amodiaquine before and after upscaling of seasonal malaria chemoprevention in seven African countries: a genomic surveillance study. Lancet Infect Dis. 2022; 23(3):361-370. DOI: 10.1016/S1473-3099(22)00593-X. View

Crameri A, Marfurt J, Mugittu K, Maire N, Regos A, Coppee J . Rapid microarray-based method for monitoring of all currently known single-nucleotide polymorphisms associated with parasite resistance to antimalaria drugs. J Clin Microbiol. 2007; 45(11):3685-91. PMC: 2168483. DOI: 10.1128/JCM.01178-07. View

10.

Cohen O, Guemas E, Menard S, Tsague Kenfack M, Talom Ngassa C, Iriart X . Effect of sulfadoxine-pyrimethamine chemoprophylaxis in pregnant women on selection of the new P. falciparum dhps quintuple mutant carrying the I431V mutation. J Antimicrob Chemother. 2023; 78(3):665-668. DOI: 10.1093/jac/dkac432. View

11.

Kirakoya-Samadoulougou F, De Brouwere V, Fottsoh Fokam A, Ouedraogo M, Ye Y . Assessing the effect of seasonal malaria chemoprevention on malaria burden among children under 5 years in Burkina Faso. Malar J. 2022; 21(1):143. PMC: 9074217. DOI: 10.1186/s12936-022-04172-z. View

12.

de Cola M, Sawadogo B, Richardson S, Ibinaiye T, Traore A, Compaore C . Impact of seasonal malaria chemoprevention on prevalence of malaria infection in malaria indicator surveys in Burkina Faso and Nigeria. BMJ Glob Health. 2022; 7(5). PMC: 9121431. DOI: 10.1136/bmjgh-2021-008021. View

13.

Amimo F, Lambert B, Magit A, Sacarlal J, Hashizume M, Shibuya K . resistance to sulfadoxine-pyrimethamine in Africa: a systematic analysis of national trends. BMJ Glob Health. 2020; 5(11). PMC: 7678238. DOI: 10.1136/bmjgh-2020-003217. View

14.

Lynch C, Pearce R, Pota H, Cox J, Abeku T, Rwakimari J . Emergence of a dhfr mutation conferring high-level drug resistance in Plasmodium falciparum populations from southwest Uganda. J Infect Dis. 2008; 197(11):1598-604. DOI: 10.1086/587845. View

15.

Cisse B, Sokhna C, Boulanger D, Milet J, Ba E, Richardson K . Seasonal intermittent preventive treatment with artesunate and sulfadoxine-pyrimethamine for prevention of malaria in Senegalese children: a randomised, placebo-controlled, double-blind trial. Lancet. 2006; 367(9511):659-67. DOI: 10.1016/S0140-6736(06)68264-0. View

16.

Konate A, Yaro J, Ouedraogo A, Diarra A, Gansane A, Soulama I . Intermittent preventive treatment of malaria provides substantial protection against malaria in children already protected by an insecticide-treated bednet in Burkina Faso: a randomised, double-blind, placebo-controlled trial. PLoS Med. 2011; 8(2):e1000408. PMC: 3032552. DOI: 10.1371/journal.pmed.1000408. View

17.

Kakuru A, Jagannathan P, Kajubi R, Ochieng T, Ochokoru H, Nakalembe M . Impact of intermittent preventive treatment of malaria in pregnancy with dihydroartemisinin-piperaquine versus sulfadoxine-pyrimethamine on the incidence of malaria in infancy: a randomized controlled trial. BMC Med. 2020; 18(1):207. PMC: 7416391. DOI: 10.1186/s12916-020-01675-x. View

18.

Desai M, Gutman J, Taylor S, Wiegand R, Khairallah C, Kayentao K . Impact of Sulfadoxine-Pyrimethamine Resistance on Effectiveness of Intermittent Preventive Therapy for Malaria in Pregnancy at Clearing Infections and Preventing Low Birth Weight. Clin Infect Dis. 2015; 62(3):323-333. PMC: 4762476. DOI: 10.1093/cid/civ881. View

19.

Maiga H, Lasry E, Diarra M, Sagara I, Bamadio A, Traore A . Seasonal Malaria Chemoprevention with Sulphadoxine-Pyrimethamine and Amodiaquine Selects Pfdhfr-dhps Quintuple Mutant Genotype in Mali. PLoS One. 2016; 11(9):e0162718. PMC: 5035027. DOI: 10.1371/journal.pone.0162718. View

20.

Gosling R, Gesase S, Mosha J, Carneiro I, Hashim R, Lemnge M . Protective efficacy and safety of three antimalarial regimens for intermittent preventive treatment for malaria in infants: a randomised, double-blind, placebo-controlled trial. Lancet. 2009; 374(9700):1521-32. DOI: 10.1016/S0140-6736(09)60997-1. View